Volume : 12, Issue : 10, October – 2025
Title:
REGULATORY ISSUES FOR IMPORT OF PHARMACEUTICAL PRODUCTS INTO INDIA
Authors :
KODIDALA POOJA *, DR. P VISHNU PRIYA, DR. D. VARUN.
Abstract :
The value of the global pharmaceutical market is expected to grow at 5 percent CAGR, to be USD 1 trillion in 2014 according to Urch publishing. The pharmaceutical industry is one of the highly regulated industries, to protect the health and well-being of the public. In the present scenario, India have stringent regulatory requirements for approval of a new drug. The single regulatory approach for marketing authorization application (MAA) of a new drug product belonging to various categories of drugs (NCE, Biologicals, Controlled Drugs etc.) is utmost difficult. Therefore, the knowledge of precise and detailed regulatory requirements for MAA of different categories of drugs should be known to establish a suitable regulatory strategy. This article focuses on the drug approval process from regulatory authorities for different categories of pharma products. Finally, there needs to be a reaffirmation and fine balance between the tenacities of gaining market access of pharmaceuticals is to protect the public health and facilitate healthy growth of pharmaceutical manufacturers. Pharmaceutical product approval process should be seen as a critical step in ensuring access to safe and effective drugs.
Keywords: CDSCO, Clinical trials, DCGI, Marketing Authorization Application, Regulatory process.
Cite This Article:
Please cite this article in press KODIDALA POOJA et al., Regulatory Issues For Import Of Pharmaceutical Products Into India , Indo Am. J. P. Sci, 2025; 12(10).
REFERENCES:
1.http://www.cdsco.nic.in/writereaddata/Guidance%20documents.pdf
2..http://www.rroij.com/open-access/regulatory-requirements-for-registration-of-pharmaceutical-to-gain-market-access-in-india.php?aid=34906
3..http://www.ich.org/fileadmin
4Suresh S , SB Puranik, Phatru Patel . Regulatory Requirements for Registration of Pharmaceutical to Gain Market Access in India. Research and reviews : journal of pharmacy and pharmaceutical sciences.
5.http://www.primaryinfo.com/market/importing-medicines.htm
6.http://www.who.int/medicines/areas/quality_safety/quality_assurance/GuidelinesImportProceduresPharmaceuticalProductsTRRS863Annex12.pdf
7.http://www.nistads.res.in/indiasnt2008/t4industry/t4ind18.htm
8.Planning Commission of India. 2006. Report of the Working Group for Drugs and Pharmaceuticals for Eleventh Five-Year Plan (Website: www.planningcommission.nic.in)
9.Schuchman, Miriam. 2007. ‘Commercializing Clinical Trials: Risks and Benefits of the CRO boom’. New England Journal of Medicine. October 4.
10.Pacific Bridge. 2007. ‘Medical Device Marketing situation in India.’
11.Gehl Sampath, Padmashree. 2008. ‘India’s Pharmaceutical Sector in 2008. Emerging Strategies and Global and Local Implications for Access to Medicines’.
12.OPPI. 2008. Indian Pharmaceutical Industry: Vision 2015.
13.Singh, Seema. 2007. ‘Indian Pharma enters the global arena’. Cell. 128 March 9. Elsevier.
14.Das, Anjan & Kumar, Subodh. 2008. ‘Innovation, IPR and Public Good’. Express Pharma Pulse. 16-31 December, 2008.
15.FICCI. 2005. White Paper on ‘Clinical Trials in India’.
16.Srivastava, D. 2008. ‘A Country level report on the pharmaceutical sector in India’. Report commissioned by DFID, UK
17.Central Drugs Standards Control Organization. (Website: www.cdsco.nic.in).